Shandong Chuangxin Pharmaceutical Research & Development Co., Ltd.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation bisoprolol amlodipine tablets and the reference preparation Kangxinan in healthy Chinese adult subjects in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study is to evaluate the safety of the test preparation bisoprolol amlodipine tablets and the reference preparation Kangxinan in healthy Chinese adult subjects.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation Ezetimibe Atorvastatin Calcium Tablets (Specifications: Each tablet contains 10 mg of ezetimibe and 20 mg of atorvastatin calcium (calculated as atorvastatin), produced by Jiangxi Shimei Pharmaceutical Co., Ltd.) and the reference preparation Ezetimibe Atorvastatin Calcium Tablets (trade name: Atozet; Specifications: Each tablet contains 10 mg of ezetimibe and 20 mg of atorvastatin calcium (calculated as atorvastatin), produced by Merck Sharp & Dohme B.V.) in healthy adult Chinese subjects in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study: To evaluate the safety of the test preparation Ezetimibe Atorvastatin Calcium Tablets and the reference preparation Ezetimibe Atorvastatin Calcium Tablets (Atozet) in healthy adult Chinese subjects.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation Rivaroxaban Granules and the reference preparation Xarelto in healthy Chinese adult subjects in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study is to evaluate the safety of the test preparation Rivaroxaban Granules and the reference preparation Xarelto in healthy Chinese adult subjects.